Carbamic acid compounds comprising an amide linkage as hdac inhibitors

A compound selected from compounds of the following formula and pharmaceutically acceptable salts thereof:

• wherein:
• A is an O- or S-containing monocyclic C5-6heteroaryl group, and is optionally substituted;
• Q1 is a partially unsaturated aliphatic C2-7alkylene group having a backbone of at least 2 carbon atoms and is optionally substituted;
• J is:
• R1 is hydrogen, C1-7alkyl, phenyl, or benzyl;
• and,
• Q2 has a backbone of at least 3 carbon atoms and is selected from:
• aliphatic C3-7alkylene, and is optionally substituted;
• phenylene, and is optionally substituted;
• phenylene-C1-7alkylene, and is optionally substituted;
• and
• C1-7alkylene-phenylene, and is optionally substituted;
• and wherein:
• if Q2 is phenylene-C1-7alkylene, then:
• (i) the C1-7alkylene moiety does not comprise a carbon-carbon triple bond;
• or
• (ii) Q2 has a backbone of less than 7 carbon atoms.

A compound selected from compounds of the following formula and pharmaceutically acceptable salts thereof:

• wherein:
• A is selected from:
• and is unsubstituted or substituted with one or more groups selected from:
• halo, hydroxyl, ether, acyl, carboxy, ester, acyloxy, amido, acylamido, thioamido, tetrazolyl, amino, nitro, cyano, thioether, sulfonic acid, sulfonate, sulfone, sulfonyloxy, sulfonamido, C1-7alkyl, C1-7haloalkyl, C1-7hydroxyalkyl, C1-7carboxyalkyl, C1-7aminoalkyl, C5-20aryl-C1-7alkyl, C3-20heterocyclyl, C5-20carboaryl, and C5-20heteroaryl;
• Q1 is —CH═CH—;
• J is:
• R1 is hydrogen or C1-7alkyl;
• and
• Q2 is selected from —(CH2)3—, —(CH2)4—, —(CH2)5—, —(CH2)6' and —(CH2)7—.